Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fair Standard Remains For Supplement, Drug Claim Substantiation – FTC

This article was originally published in The Tan Sheet

Executive Summary

The Federal Trade Commission says consent orders that require more clinical tests to substantiate health claims than are required for other product categories are fair because they are based on the nature of the claims, agency officials say.

You may also be interested in...



Sweeping Change At FTC May Sweep Away RCT Standard For Health Claims

Confirmations by the Senate mark FTC ’s first-ever complete leadership turnover at once and fill out the roster for the first time since President Trump’s election in 2016. The agency has been operating with two commissioners since soon after the election.

FTC Actions On Supplement Claim Substantiation Put Industry On Alert

Substantiation “is not defined by one study or two studies and by whether the FTC likes that study or not,” attorney Todd Harrison says at CRN’s annual convention. Scott Bass, an attorney who worked on writing DSHEA, says “FTC has declared, at least informally, ‘We don’t care about FDA law.’”

FTC Actions On Supplement Claim Substantiation Put Industry On Alert

Substantiation “is not defined by one study or two studies and by whether the FTC likes that study or not,” attorney Todd Harrison says at CRN’s annual convention. Scott Bass, an attorney who worked on writing DSHEA, says “FTC has declared, at least informally, ‘We don’t care about FDA law.’”

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS105336

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel